Covid vaccine: Covaxin Phase-3 efficacy data by March, says Bharat Biotech CMD
The Bharat Biotech chairman Dr Krishna Ella also mentioned that there has been no interim analysis of the efficacy in the Phase 3 trials has been done so far
'Currently, we have 20 million doses. We are aiming to achieve 700 million doses capacity in four facilities,' he informed
Hyderabad-based Bharat Biotech, which received emergency use approval for its coronavirus vaccine 'Covaxin' on Sunday from India's drug regulator, virtually addressed a press conference today.